Precision medicine, also referred to as personalized or individualized medicine, is experiencing significant growth and is revolutionizing the approach to disease prevention and treatment. This innovative field has been fueled by advancements in diagnostic tools, informatics development, and a deeper understanding of genomic and proteomic interactions.
This novel approach to medicine takes individual variability in genes, environment, and lifestyle into account to design specific and adaptive treatments and patient support. It utilizes precise diagnostic tools such as DNA sequencing and medical imaging, often involving robust calculating tools to evaluate the results. These advancements have led to the identification of biomarkers and the development of tailored medical interventions for targeted diseases.
The application of precision medicine encompasses various categories, including oncology/pedo-oncology, pharmacogenomics, inherited diseases, and prognosis and prevention, which has allowed new players in the healthcare industry to thrive.
An analysis of the technology landscape of precision medicine through IP analysis provides a comprehensive understanding of the environment and identifies key insights about the forces at play. Understanding the trends and targeted applications reveals that precision medicine technologies have been in place since the beginning of the 21st century.
More than 2,000 patent applications were filed in 2003, focusing on diagnostic/prognosis methods. The real surge in precision medicine innovations occurred after 2010, with an increase in patent filings and a shift towards tailored therapy. The integration of AI-based technologies in precision medicine has also been on the rise, constituting 20% of patent applications filed in 2022.
The primary targeted application of precision medicine has been in oncology, with disclosed innovations directed at screening and identifying tumor biomarkers, profiling the tumor to understand tumor heterogeneity, and developing targeted therapies such as cell therapies and immunotherapies.
In addition to pharmaceutical companies and research institutes, major tech corporations such as Philips, IBM, and Samsung have played a significant role in developing diagnostic/prognosis tools crucial for the delivery of personalized care, highlighting the importance of tech innovation in precision medicine.
A thorough analysis of the key technological areas and main players is essential for understanding the precision medicine landscape. This analysis can support strategic R&D orientation, product development, competitive intelligence reports, IP valuation, and technological transfer.
As precision medicine continues to advance, it is crucial to stay informed about the latest technological innovations and market trends. IP analysis provides valuable insights into the technological landscape of precision medicine, from innovation white spaces to competitor activity, IP value, licensing, and technological transfer.
In conclusion, the precision medicine landscape is rapidly evolving due to technological advancements and a deeper understanding of genomics and proteomics. Through IP analysis, businesses can gain valuable intelligence to navigate this dynamic field and capitalize on emerging opportunities.
To access the full article, click here.
Author:
Steven Nindorera-Badara
Business Intelligence Senior Consultant at Questel.
+ There are no comments
Add yours